Nuclear cIAP1 overexpression is a tumor stage- and grade-independent predictor of poor prognosis in human bladder cancer patients

Urologic Oncology: Seminars and Original Investigations

Volumn 30, Issue 4, 2012, Pages 450-456

  Che, Xiangyu ^a   Yang, Deyong ^a   Zong, Huafeng ^b   Wang, Jianbo ^a   Li, Xiancheng ^a   Chen, Feng ^a   Chen, Xiaochi ^a   Song, Xishuang ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

^b Dalian Friendship Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 1; CELLULAR INHIBITOR OF APOPTOSIS PROTEIN 2; INHIBITOR OF APOPTOSIS PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN 2; KI 67 ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CELL NUCLEUS; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION PROFILING; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84862976953     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2010.12.016     Document Type: Article

References (28)

1. Babjuk M., Oosterlinck W., Sylvester R., et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008, 54:303-314.
2. Kamat A.M., Lamm D.L. Intravesical therapy for bladder cancer. Urology 2000, 55:161-168.
3. Song X., Yang D., Che X., et al. Comparing the safety and efficiency of conventional monopolar, plasmakinetic, and holmium laser transurethral resection of primary non-muscle invasive bladder cancer. J Endourol 2010, 24:69-73.
4. Sylvester R.J., van der Meijden A.P., Oosterlinck W., et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: A combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006, 49:466-475.
5. Metwalli A.R., Khanbolooki S., Jinesh G., et al. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 2010, 10:885-892.
6. LaCasse E.C., Mahoney D.J., Cheung H.H., et al. IAP-targeted therapies for cancer. Oncogene 2008, 27:6252-6275.
7. Fischer U., Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol Rev 2005, 57:187-215.
8. Verhagen A.M., Coulson E.J., Vaux D.L. Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs. Genome Biol 2001, 2. REVIEWS3009.
9. Vaux D.L., Silke J. Mammalian mitochondrial IAP binding proteins. Biochem Biophys Res Commun 2003, 304:499-504.
10. Saelens X., Festjens N., Vande W.L., et al. Toxic proteins released from mitochondria in cell death. Oncogene 2004, 23:2861-2874.
11. Schimmer A.D. Inhibitor of apoptosis proteins: Translating basic knowledge into clinical practice. Cancer Res 2004, 64:7183-7190.
12. Dubrez-Daloz L., Dupoux A., Cartier J. IAPs: More than just inhibitors of apoptosis proteins. Cell Cycle 2008, 7:1036-1046.
13. Vucic D., Fairbrother W.J. The inhibitor of apoptosis proteins as therapeutic targets in cancer. Clin Cancer Res 2007, 13:5995-6000.
14. Rothe M., Pan M.G., Henzel W.J., et al. The TNFR2-TRAF signaling complex contains two novel proteins related to baculoviral inhibitor of apoptosis proteins. Cell 1995, 83:1243-1252.
15. Dai Y., Lawrence T.S., Xu L. Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 2009, 1:1-15.
16. Psyrri A., Yu Z., Bamias A., et al. Evaluation of the prognostic value of cellular inhibitor of apoptosis protein in epithelial ovarian cancer using automated quantitative protein analysis. Cancer Epidemiol Biomarkers Prev 2006, 15:1179-1183.
17. Jonsson G., Paulie S., Grandien A. cIAP-2 block apoptotic events in bladder cancer cells. Anticancer Res 2003, 23:3311-3316.
18. Bertrand M.J., Milutinovic S., Dickson K.M., et al. cIAP1 and cIAP2 facilitate cancer cell survival by functioning as E3 ligases that promote RIP1 ubiquitination. Mol Cell 2008, 30:689-700.
19. Hu S., Yang X. Cellular inhibitor of apoptosis 1 and 2 are ubiquitin ligases for the apoptosis inducer Smac/DIABLO. J Biol Chem 2003, 278:10055-10060.
20. Deveraux Q.L., Roy N., Stennicke H.R., et al. IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J 1998, 17:2215-2223.
21. Vischioni B., Giaccone G., Span S.W., et al. Nuclear shuttling and TRAF2-mediated retention in the cytoplasm regulate the subcellular localization of cIAP1 and cIAP2. Exp Cell Res 2004, 298:535-548.
22. Jin H.S., Lee T.H. Cell cycle-dependent expression of cIAP2 at G2/M phase contributes to survival during mitotic cell cycle arrest. Biochem J 2006, 399:335-342.
23. Levkau B., Garton K.J., Ferri N., et al. xIAP induces cell-cycle arrest and activates nuclear factor-κB: New survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res 2001, 88:282-290.
24. Ye L., Song X., Li S., et al. Livin-α promotes cell proliferation by regulating G(1)-S cell cycle transition in prostate cancer. Prostate 2011, 71:42-51.
25. Xia F., Canovas P.M., Guadagno T.M., et al. A survivin-Ran complex regulates spindle formation in tumor cells. Mol Cell Biol 2008, 28:5299-5311.
26. Tanimoto T., Tsuda H., Imazeki N., et al. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett 2005, 224:141-151.
27. Liu S.S., Tsang B.K., Cheung A.N., et al. Anti-apoptotic proteins, apoptotic and proliferative parameters, and their prognostic significance in cervical carcinoma. Eur J Cancer 2001, 37:1104-1110.
28. Mace P.D., Smits C., Vaux D.L., et al. Asymmetric recruitment of cIAPs by TRAF2. J Mol Biol 2010, 400:8-15.